Shandong Boan Biotechnology Co (HKSE:06955) Change In Payables And Accrued Expense : HK$0.0 Mil (TTM As of Dec. 2023)

View and export this data going back to 2022. Start your Free Trial

What is Shandong Boan Biotechnology Co Change In Payables And Accrued Expense?

Shandong Boan Biotechnology Co's Change In Payables And Accrued Expense for the quarter that ended in Dec. 2023 was HK$0.0 Mil. It means Shandong Boan Biotechnology Co's Accounts Payable & Accrued Expense stayed the same from Jun. 2023 to Dec. 2023 .

Shandong Boan Biotechnology Co's Change In Payables And Accrued Expense for the fiscal year that ended in Dec. 2023 was HK$0.0 Mil. It means Shandong Boan Biotechnology Co's Accounts Payable & Accrued Expense stayed the same from Dec. 2022 to Dec. 2023 .

Shandong Boan Biotechnology Co Change In Payables And Accrued Expense Historical Data

The historical data trend for Shandong Boan Biotechnology Co's Change In Payables And Accrued Expense can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Shandong Boan Biotechnology Co Change In Payables And Accrued Expense Chart

Shandong Boan Biotechnology Co Annual Data

Trend

Dec20

Dec21

Dec22

Dec23

Change In Payables And Accrued Expense

Shandong Boan Biotechnology Co Semi-Annual Data
	Dec20	Jun21	Dec21	Jun22	Dec22	Jun23	Dec23
Change In Payables And Accrued Expense	Get a 7-Day Free Trial			-	-	-	-	-

Shandong Boan Biotechnology Co Change In Payables And Accrued Expense Calculation

Change In Payables And Accrued Expense is the increase or decrease between periods of the Accounts Payable & Accrued Expense. Accrued expenses represent expenses incurred at the end of the reporting period but not yet paid; also called accrued liabilities. The accrued liability is shown under Liabilities section in the balance sheet.

Change In Payables And Accrued Expense for the trailing twelve months (TTM) ended in Dec. 2023 adds up the semi-annually data reported by the company within the most recent 12 months, which was HK$0.0 Mil.

Shandong Boan Biotechnology Co Change In Payables And Accrued Expense Related Terms

Thank you for viewing the detailed overview of Shandong Boan Biotechnology Co's Change In Payables And Accrued Expense provided by GuruFocus.com. Please click on the following links to see related term pages.

Shandong Boan Biotechnology Co (HKSE:06955) Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Shandong Boan Biotechnology Co Ltd (HKSE:06955) » Definitions » Change In Payables And Accrued Expense

Comparable Companies

Traded in Other Exchanges

UJ9:Germany

Address

No. 39 Keji Avenue, High-Tech Industrial Development Zone, Shandong Province, Yantai, CHN

Website

https://www.boan-bio.com

Shandong Boan Biotechnology Co Ltd is a fully integrated biopharmaceutical company. The company is engaged in the development, manufacture, and commercialization of high-quality biologics in China and around the world. It focuses on areas such as oncology, metabolism, autoimmunity, and ophthalmology. Geographically company's revenue is generated from customers located in Mainland China.

Executives

Asiapharm Investments Ltd.
Ginkgo (ptc) Limited
Liu Dianbo
Luye Life Sciences Group Ltd
Luye Pharma Holdings Ltd.
Luye Pharma Hong Kong Limited
Luye Pharmaceutical International Co., Ltd.
Luye Pharmaceutical Investment Co., Ltd.
Nelumbo Investments Limited
Shorea Lbg
Luye Pharma Group Ltd.
Shan Dong Lv Ye Zhi Yao You Xian Gong Si
Yan Tai Lv Ye Yi Yao Kong Gu Ji Tuan You Xian Gong Si
Li Li	2201 Interest of corporation controlled by you

Shandong Boan Biotechnology Co (HKSE:06955) Headlines

No Headlines